Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial.
Retèl VP, Byng D, Linn SC, Jóźwiak K, Koffijberg H, Rutgers EJ, Cardoso F, Piccart MJ, Poncet C, Van't Veer LJ, van Harten WH. Retèl VP, et al. Among authors: van harten wh, van t veer lj. Eur J Cancer. 2020 Sep;137:193-203. doi: 10.1016/j.ejca.2020.07.002. Epub 2020 Aug 11. Eur J Cancer. 2020. PMID: 32795875 Free article. Clinical Trial.
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Bueno-de-Mesquita JM, van Harten WH, Retel VP, van 't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC. Bueno-de-Mesquita JM, et al. Among authors: van harten wh, van t veer lj, van dam fs, van krimpen c, van de vijver mj, van tinteren h. Lancet Oncol. 2007 Dec;8(12):1079-1087. doi: 10.1016/S1470-2045(07)70346-7. Epub 2007 Nov 26. Lancet Oncol. 2007. PMID: 18042430
Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics.
Retèl VP, Bueno-de-Mesquita JM, Hummel MJ, van de Vijver MJ, Douma KF, Karsenberg K, van Dam FS, van Krimpen C, Bellot FE, Roumen RM, Linn SC, van Harten WH. Retèl VP, et al. Among authors: van harten wh, van dam fs, van krimpen c, van de vijver mj. Int J Technol Assess Health Care. 2009 Jan;25(1):73-83. doi: 10.1017/S0266462309090102. Int J Technol Assess Health Care. 2009. PMID: 19126254
Tumour tissue: who is in control?
Ploem MC, Retèl VP, Linn SC, van Boven HH, Schmidt MK, de Jong JP, Gevers JK, van Harten WH. Ploem MC, et al. Among authors: van boven hh, van harten wh. Lancet Oncol. 2010 Jan;11(1):9-11. doi: 10.1016/S1470-2045(09)70318-3. Epub 2009 Oct 31. Lancet Oncol. 2010. PMID: 19880349 No abstract available.
Design of the Physical exercise during Adjuvant Chemotherapy Effectiveness Study (PACES): a randomized controlled trial to evaluate effectiveness and cost-effectiveness of physical exercise in improving physical fitness and reducing fatigue.
van Waart H, Stuiver MM, van Harten WH, Sonke GS, Aaronson NK. van Waart H, et al. Among authors: van harten wh. BMC Cancer. 2010 Dec 7;10:673. doi: 10.1186/1471-2407-10-673. BMC Cancer. 2010. PMID: 21138561 Free PMC article. Clinical Trial.
201 results